Original Article
Efficacy of Goshajinkigan for Peripheral Neurotoxicity of Oxaliplatin in Patients with Advanced or Recurrent Colorectal Cancer
Table 5
Reasons for discontinuation of therapy.
| | Group A, | Group B, | Group C, | Group D, | Total, | | Pts (%) | Pts (%) | Pts (%) | Pts (%) | Pts (%) |
| | Progressive disease | 2 (18.2) | 1 (7.1) | 1 (4.8) | 9 (20.5) | 13 (14.4) | | Others | | | | | | | Neuropathy | 0 | 6 (42.9) | 4 (19.0) | 10 (22.7) | 20 (22.2) | | Myelosuppression | 2 (18.2) | 1 (7.1) | 0 | 3 (6.8) | 6 (6.7) | | Allergy | 0 | 0 | 2 (9.5) | 3 (6.8) | 5 (5.6) | | Other toxicities | 1 (9.1) | 2 (14.3) | 7 (33.3) | 9 (20.5) | 19 (21.1) | | Resection | 1 (9.1) | 2 (14.3) | 3 (14.3) | 1 (2.3) | 7 (7.8) | | Patient refusal | 0 | 1 (7.1) | 0 | 0 | 1 (1.1) | | Change of therapy | 0 | 0 | 0 | 5 (11.4) | 5 (5.6) | | Continuing | 5 (45.5) | 1 (7.1) | 4 (19.0) | 4 (9.1) | 14 (15.6) |
|
|
Group A, GJG; Group B, Ca/Mg; Group C, GJG + Ca/Mg; Group D, no therapy.
GJG, goshajinkigan; Ca, calcium gluconate; Mg, magnesium sulfate.
|
